Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysisEric M. Thompson, Tibor Hortobágyi, Roger E. McLendon et al.|The Lancet Oncology|2016Cited by 369
10097-ACT-6 PHASE 1/2, PROSPECTIVE, INTERNATIONAL MULTI-CENTER STUDY TO ESTABLISH THE SAFETY AND FEASIBILITY OF BLOOD-BRAIN-BARRIER DISRUPTION COMBINED WITH CARBOPLATIN FOR RECURRENT GLIOBLASTOMA; FIRST CLINICAL EXPERIENCE IN JAPANNoriyuki Kijima, Haruhiko Kishima, Satoru Oshino et al.|Neuro-Oncology Advances|2023Cited by 1
ACT-20 PHASE 1/2, PROSPECTIVE, INTERNATIONAL MULTI-CENTER STUDY TO ESTABLISH THE SAFETY AND FEASIBILITY OF BLOOD-BRAIN-BARRIER DISRUPTION COMBINED WITH CARBOPLATIN FOR RECURRENT GLIOBLASTOMA; FIRST CLINICAL EXPERIENCE IN JAPANNoriyuki Kijima, Haruhiko Kishima, Manabu Kanemoto et al.|Neuro-Oncology Advances|2022Cited by 0